Anjarium Biosciences AG, a Swiss company with technology for delivering gene therapies to patients without the use of a viral vector, has raised CHF 55.5 million (€50.96 million) from a group of investors co-led by Gimv and Abingworth LLP. The money will be used to expand the company’s staff and advance several of its programmes towards the clinic.
